1005791-26-3

Upstream product

• 1005791-46-7 ethyl 2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}-2-methylpropanoate 

Relevant academic research and scientific papers

BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY

The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of the beta-3 adrenergic receptor as medicaments.

Stereospecific synthesis and bio-activity of novel β3-adrenoceptor agonists and inverse agonists

Since it is widely distributed into the body, β3-adrenoceptor is becoming an attractive target for the treatment of several pathologies such as obesity, type 2 diabetes, metabolic syndrome, cachexia, overactive bladder, ulcero-inflammatory disorder of the gut, preterm labour, anxiety and depressive disorders, and heart failure. New compounds belonging to the class of arylethanolamines bearing one or two stereogenic centres were prepared in good yields as racemates and optically active forms. They were, then, evaluated for their intrinsic activity towards β3-adrenoceptor and their affinity for β1- and β2-adrenergic receptors. Stereochemical features were found to play a crucial role in determining the behaviour of such compounds. In particular, α-racemic, (αR)- and (αS)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}-2- methylpropanoic acid, (α-rac, β-rac)-, (αR, βS)- and (αR, βR)- 2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid were found to be endowed with β3-adrenoceptor agonistic activity. Whereas, (αS, βS)- and (αS, βR)-2-{4-[2-(2-hydroxy-2-phenylethylamino)ethyl]phenoxy}propanoic acid behaved as β3-adrenoceptor inverse agonists. Such compounds showed no affinity for β1- and β2-adrenergic receptor, respectively. Thus, resulting highly selective β3-adrenoceptor ligands.